Search Results

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant failed to meet the primary and key secondary endpoint in the first of three identical Phase III studies.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, announced that the Company will participate in two investor conferences in May.

Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced the initiation of a Phase 1b study evaluating NMRA-511 for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD).

Neumora Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, announced the initiation of a Phase 2 study evaluating the safety and efficacy of navacaprant in people with bipolar depression.

Neumora Therapeutics, Inc. today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and chief executive officer.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration.